Drug intelligence / Profile preview

Kangquanli

Development stage: Preclinical
Lead developer: Nutricia
Administration: Oral

Overview

**Kangquanli** is a diabetes-oriented enteral nutritional suspension marketed in China as enteral nutrition suspension (TPF-DM). It is a ready-to-use, nutritionally complete heterogeneous formula intended for oral or tube feeding in patients with preserved or partial gastrointestinal function who cannot obtain adequate nutrition from ordinary food and require glycemic control. It provides macronutrients, dietary fiber, vitamins, minerals, and trace elements rather than acting through a discrete pharmacologic receptor target. A registered randomized study evaluated Kangquanli plus medical nutrition therapy in gestational diabetes mellitus. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=205999))

Brand names: Kangquanli
Other names: Enteral nutrition suspension (TPF-DM)肠内营养混悬液 (TPF-DM)康全力

Beyond the preview

Go deeper on Kangquanli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangquanli.

Explore the full profile